Macrophage interferon regulatory factor 7 aggravates the progression of metabolic dysfunction-associated steatohepatitis.
6 affiliations
- 1Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
- 2Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- 3School of Biological Science & Medical Engineering, Southeast University, Nanjing, China.
- 4Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China. [email protected].
- 5Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China. [email protected].
- 6Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China. [email protected].
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) represents a growing clinical burden with increasing prevalence and lacking approved pharmacological therapies. Interferon regulatory factor 7 (IRF7) is a central mediator of type I interferon-dependent immune responses, yet the precise mechanisms by which macrophage-expressed IRF7 shapes inflammatory and metabolic events during MASH pathogenesis remain incompletely defined. This study aimed to dissect the functional role of IRF7 in MASH development. We assessed IRF7 expression in human and mouse liver specimens, and utilized myeloid-specific Irf7-deficient mice fed with high-fat high-cholesterol diet (HFHCD) or methionine-choline-deficient diet (MCD) to recapitulate MASH pathology. IRF7 was significantly elevated in MASH-affected livers, and myeloid-specific Irf7 deletion markedly mitigated MASH progression. Mechanistically, loss of IRF7 blunted IFN-α and IFN-β production, suppressing macrophage-derived type I interferon-dependent immune cascades. IRF7 directly bound to the promoters of pro-inflammatory Tnfa and Il1b to boost their transcription, and interacted with SMAD3 to activate Tgfb1 transcription. The E3 ubiquitin ligase HUWE1 mediated IRF7 monoubiquitination to enhance its nuclear translocation, driving transcription of pro-inflammatory and pro-fibrotic genes. This molecular cascade aggravated hepatic steatosis and triggered hepatic stellate cell (HSC) activation, accelerating MASH deterioration. Pharmacological IRF7 inhibition effectively counteracted these pathological alterations. Collectively, myeloid IRF7 fuels MASH progression by amplifying macrophage-mediated liver inflammation, suggesting IRF7 as a promising therapeutic target against MASH.
Related
- Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis
- Successive and Isoform-Specific Remodeling of Hepatic Drug-Metabolizing Enzymes during Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis Progression
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) : A systematic review and meta-analysis
- Commentary: Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis
- GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials
BibTeX
@article{ni2026macrophage,
title = {{Macrophage interferon regulatory factor 7 aggravates the progression of metabolic dysfunction-associated steatohepatitis.}},
author = {Xuhao Ni and Qingfa Bu and Yuan Liang and Bozhou Pan and Jian Wang and Qingxiang Xu and Lei Liu and Qi Wang},
journal = {Molecular biomedicine},
year = {2026},
month = oct,
doi = {10.1186/s43556-026-00601-6},
url = {https://europepmc.org/article/MED/42895693},
note = {CC BY},
}
RIS
TY - JOUR
TI - Macrophage interferon regulatory factor 7 aggravates the progression of metabolic dysfunction-associated steatohepatitis.
AU - Xuhao Ni
AU - Qingfa Bu
AU - Yuan Liang
AU - Bozhou Pan
AU - Jian Wang
AU - Qingxiang Xu
AU - Lei Liu
AU - Qi Wang
PY - 2026
DA - 2026/10/19
JO - Molecular biomedicine
DO - 10.1186/s43556-026-00601-6
UR - https://europepmc.org/article/MED/42895693
AB - Metabolic dysfunction-associated steatohepatitis (MASH) represents a growing clinical burden with increasing prevalence and lacking approved pharmacological therapies. Interferon regulatory factor 7 (IRF7) is a central mediator of type I interferon-dependent immune responses, yet the precise mechanisms by which macrophage-expressed IRF7 shapes inflammatory and metabolic events during MASH pathogenesis remain incompletely defined. This study aimed to dissect the functional role of IRF7 in MASH development. We assessed IRF7 expression in human and mouse liver specimens, and utilized myeloid-specific Irf7-deficient mice fed with high-fat high-cholesterol diet (HFHCD) or methionine-choline-deficient diet (MCD) to recapitulate MASH pathology. IRF7 was significantly elevated in MASH-affected livers, and myeloid-specific Irf7 deletion markedly mitigated MASH progression. Mechanistically, loss of IRF7 blunted IFN-α and IFN-β production, suppressing macrophage-derived type I interferon-dependent immune cascades. IRF7 directly bound to the promoters of pro-inflammatory Tnfa and Il1b to boost their transcription, and interacted with SMAD3 to activate Tgfb1 transcription. The E3 ubiquitin ligase HUWE1 mediated IRF7 monoubiquitination to enhance its nuclear translocation, driving transcription of pro-inflammatory and pro-fibrotic genes. This molecular cascade aggravated hepatic steatosis and triggered hepatic stellate cell (HSC) activation, accelerating MASH deterioration. Pharmacological IRF7 inhibition effectively counteracted these pathological alterations. Collectively, myeloid IRF7 fuels MASH progression by amplifying macrophage-mediated liver inflammation, suggesting IRF7 as a promising therapeutic target against MASH.
SN - 2662-8651
ER -